A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples